GN Celebrates Grand Opening of New North American HQ
GN has officially opened its new 218,000-square-foot North American headquarters in Shakopee, Minnesota, establishing a modern manufacturing and distribution hub for all GN brands.
GN has officially opened its new 218,000-square-foot North American headquarters in Shakopee, Minnesota, establishing a modern manufacturing and distribution hub for all GN brands.
Marshall Chasin, AuD, a longtime contributor and member of The Hearing Review editorial advisory board, is the recipient of this year's Richard Seewald Career Award from the Canadian Academy of Audiology.
HIA's MarkeTrak 2025 study of the U.S. hearing loss market provides new data on prescription hearing aids, OTC devices, and emerging technologies.
Regeneron’s DB-OTO gene therapy for genetic hearing loss is one of nine drugs to receive expedited review under FDA's new CNPV program.
The Audiology Practice Standards Organization is inviting public review and comment on its new draft standard to ensure profession-supported best practices in tinnitus evaluation.
Neuromod Devices has achieved both Medical Device Single Audit Program (MDSAP) and EU Medical Device Regulation (MDR) certification, enabling expanded global availability of its Lenire tinnitus treatment device in Europe, Canada, Australia, and beyond.
Gene Brown, MD, RPh, has been elected president of the American Academy of Otolaryngology–Head and Neck Surgery and its foundation.
Updated pivotal trial results show that Regeneron’s investigational gene therapy DB-OTO led to rapid, clinically meaningful, and sustained hearing improvements in nearly all children with OTOF-related profound genetic hearing loss, with some achieving normal hearing and improved speech development.
Doctoral students in Audiology from across the U.S. attended the 2025 Oticon Summer Camp for real-world clinical practice and career development.